{
    "Rank": 971,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01472146",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "Zo-neo2011"
                },
                "Organization": {
                    "OrgFullName": "Instituto Nacional de Cancer, Brazil",
                    "OrgClass": "OTHER_GOV"
                },
                "BriefTitle": "ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer",
                "OfficialTitle": "Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "May 2017",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "October 2011",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "July 2016",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "May 2017",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "September 20, 2011",
                "StudyFirstSubmitQCDate": "November 11, 2011",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "November 16, 2011",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "May 4, 2017",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "May 9, 2017",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor-Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Susanne Crocamo",
                    "ResponsiblePartyInvestigatorTitle": "Clinical Oncologist",
                    "ResponsiblePartyInvestigatorAffiliation": "Instituto Nacional de Cancer, Brazil"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Susanne Crocamo",
                    "LeadSponsorClass": "OTHER_GOV"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "The purpose of this study is to evaluate the association of zoledronic acid with standard treatment with anthracycline followed taxane plus trastuzumab in locally advanced breast cancer HER 2 positive.",
                "DetailedDescription": "This trial combines zolendronic acid with anthracycline followed taxane plus trastuzumab for neoadjuvant treatment of HER 2 positive stage II/III breast cancer.\n\nZoledronic acid (ZOL) has activity of anti-bone resorption and shows diverse anti-tumor effects in vitro. Some chemical and biological characteristics of ZOL indicate potential for inhibition of tumor growth in pre clinical studies\n\nThe primary objective of the study is to evaluate the residual cancer burden (RCB) with the addition of zolendronic acid to standard neoadjuvant therapy. RCB is calculated as a continuous index combining pathologic measurements of primary tumor (size and cellularity) and nodal metastases (number and size). RCB index is a significant predictor of distant relapse-free survival, and can be used to define categories of near-complete response and chemotherapy resistance after neoadjuvant chemotherapy compared with currently used risk factors. Additionally, the study will collect tissue biopsies and blood before and after treatment in order to correlate clinical outcomes with gene expression and radiologic data to predictive response."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer",
                        "Breast Disease",
                        "Neoplasms",
                        "Neoplasms by Site"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Neoadjuvant therapy",
                        "Breast cancer HER2 positive",
                        "zolendronic acid"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "58",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Zometa neoadjuvant HER2 breast cancer",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Zo-Nantax arm - Neoadjuvant chemotherapy with association of zoledronic acid and standard treatment with anthracycline followed taxane plus trastuzumab in locally advanced breast cancer HER2 positive HR positive/negative.\n\nDrug:Cyclophosphamide Drug:Adriamycin Drug:Docetaxel Drug:Trastuzumab Drug:Zolendronic acid",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: Zo-Nantax"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Zo-Nantax",
                            "InterventionDescription": "Experimental:\n\nAC,Docetaxel,Trastuzumab,Zolendronate\n\nDrug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles\n\nDrug: Docetaxel\n\nDocetaxel 100 mg/m2 every 21 days for 4 cycles.\n\nDrug: Trastuzumab\n\nTrastuzumab 8mg/kg [loading dose] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.\n\nDrug: zolendronic acid\n\nZolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Zometa neoadjuvant HER2 breast cancer"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Other Names:",
                                    "Adriblastine RD",
                                    "Cytoxan",
                                    "Taxotere\u00ae",
                                    "Herceptin\u00ae",
                                    "Zometa"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Evaluate the residual cancer burden (RCB)",
                            "PrimaryOutcomeDescription": "Use MD Anderson calculator to quantify the minimal residual disease",
                            "PrimaryOutcomeTimeFrame": "6 months"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Assessing the tolerance to standard neoadjuvant treatment plus zolendronic acid,according to the common toxicity criteria Terminology Criteria for Adverse Events version 3.0.",
                            "SecondaryOutcomeDescription": "CTC 4.0",
                            "SecondaryOutcomeTimeFrame": "6 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Assessment of the difference in gene expression according to treatment response",
                            "SecondaryOutcomeDescription": "Through microarray assays",
                            "SecondaryOutcomeTimeFrame": "6 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Prediction of pathological response by MRI calculated from the sequence of apparent diffusion coefficient (ADC)",
                            "SecondaryOutcomeDescription": "Make MRI before the start of chemotherapy, after the second cycle and before surgery, and evaluate the changes in the diffusion of water",
                            "SecondaryOutcomeTimeFrame": "4 months"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nStage IIA to IIIB HER-2 positive breast cancer\nECOG performance \u2264 2\n\nAdequate hematologic function with:\n\nAbsolute neutrophil count (ANC)> 1500/mm\u00b3\nPlatelets \u2265 100.000/mm\u00b3\nhemoglobin \u2265 9g/dL\n\nAdequate hepatic and renal function with:\n\nSerum bilirubin \u2264 1.5 x the institutional upper limit of normal (ULN)\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT)\u2264 2.5 x the institutional upper limit of normal (ULN)\nAlkaline phosphatase )\u2264 2.5 x the institutional upper limit of normal (ULN)\nSerum creatinine \u2264 1.5 x the institutional upper limit of normal (ULN) or calculated creatinine clearance > 50 mL/min\n\nAdequate cardiac function\n\nLeft ventricular ejection fraction (LVEF)with institutional normal range\nKnowledge of the investigational nature of the study and ability to provide consent for study participation\n\nExclusion Criteria:\n\nPrevious diagnostic of breast or other cancer\nPregnancy\nMetastatic breast cancer\nBilateral, synchronous breast cancer\nAny other disease(s), psychiatric condition, metabolic dysfunction, that contraindicates the use of study drugs or that woud make the patient inappropriate for this study\nNeuropathy grade > 2 by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "MaximumAge": "75 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Susanne C Costa, MD",
                            "OverallOfficialAffiliation": "Hospital do Cancer III - INCA",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Hospital do Cancer III - INCA",
                            "LocationCity": "Rio de Janeiro",
                            "LocationZip": "20560-120",
                            "LocationCountry": "Brazil"
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No",
                "IPDSharingDescription": "I don't plan to share IPD"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000009369",
                            "ConditionMeshTerm": "Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000009371",
                            "ConditionMeshTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionMeshId": "D000001941",
                            "ConditionMeshTerm": "Breast Diseases"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafAsFound": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000004317",
                            "InterventionMeshTerm": "Doxorubicin"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000000903",
                            "InterventionAncestorTerm": "Antibiotics, Antineoplastic"
                        },
                        {
                            "InterventionAncestorId": "D000059005",
                            "InterventionAncestorTerm": "Topoisomerase II Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000059003",
                            "InterventionAncestorTerm": "Topoisomerase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M1668",
                            "InterventionBrowseLeafName": "Docetaxel",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M325",
                            "InterventionBrowseLeafName": "Trastuzumab",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M6417",
                            "InterventionBrowseLeafName": "Cyclophosphamide",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M1699",
                            "InterventionBrowseLeafName": "Zoledronic Acid",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M147850",
                            "InterventionBrowseLeafName": "Taxane",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7182",
                            "InterventionBrowseLeafName": "Doxorubicin",
                            "InterventionBrowseLeafAsFound": "Juvenile",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M227283",
                            "InterventionBrowseLeafName": "Liposomal doxorubicin",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3912",
                            "InterventionBrowseLeafName": "Anti-Bacterial Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3914",
                            "InterventionBrowseLeafName": "Antibiotics, Antitubercular",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ARhu",
                            "InterventionBrowseBranchName": "Antirheumatic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "BDCA",
                            "InterventionBrowseBranchName": "Bone Density Conservation Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Infe",
                            "InterventionBrowseBranchName": "Anti-Infective Agents"
                        }
                    ]
                }
            }
        }
    }
}